Non-small Cell Lung Cancer
📧 Sign up to get email alerts when something new happens for Non-small Cell Lung Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-08-22Clinical Trial Update: Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008) [Phase 3]
Phase 3 trial evaluating pembrolizumab plus lenvatinib versus docetaxel in metastatic non-small cell lung cancer after platinum doublet chem…
-
CLINICAL_TRIALS trial_result · 2024-08-22Clinical Trial Update: A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors [Phase 1, Phase 2]
Cantargia AB's CAN04 first-in-human study in solid malignant tumors (Phase 1/2) has completed. The trial encompassed several indications, in…
-
CLINICAL_TRIALS trial_result · 2024-08-22Clinical Trial Update: Sirolimus and Durvalumab for the Treatment of Stage I-IIIA Non-small Cell Lung Cancer [Phase 1]
Phase 1 trial evaluating sirolimus in combination with durvalumab for stage I–IIIA non-small cell lung cancer. The study is terminated with …
-
CLINICAL_TRIALS trial_result · 2024-08-22Clinical Trial Update: Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLC [Phase 2]
Phase 2 trial evaluating biomarkers of response to the combination of ipilimumab and nivolumab as first-line therapy for non-small cell lung…
-
CLINICAL_TRIALS research · 2024-08-22Clinical Trial Update: Befotertinib Adjuvant Therapy in Stage IA2-IB NSCLC Patients [Phase 4]
Phase 4 trial updates Befotertinib as adjuvant therapy for stage IA2-IB non-small cell lung cancer; the study is currently recruiting and ex…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2024-08-21Clinical Trial Update: Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer [Phase 1]
This is a Phase 1 clinical trial update evaluating the combination of osimertinib and navitoclax in patients with EGFR-positive, previously …
-
CLINICAL_TRIALS trial_result · 2024-08-21Clinical Trial Update: AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and in Patients With Non-Small-Cell Lung Cancer [Phase 1]
Phase 1 trial update evaluating AZD9150 alone or with durvalumab, with or without chemotherapy, in patients with advanced solid tumors and n…
-
CLINICAL_TRIALS trial_result · 2024-08-21Clinical Trial Update: Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors [Phase 1]
Phase 1 study evaluating the combination of everolimus and vatalanib in patients with advanced solid tumors, including several neuroendocrin…
-
CLINICAL_TRIALS research · 2024-08-21Clinical Trial Update: Immunotherapy and Carbon Ion Radiotherapy In Solid Cancers With Stable Disease [Phase 2]
Phase 2 clinical trial exploring immunotherapy combined with carbon ion radiotherapy in solid cancers with stable disease, currently recruit…
-
CLINICAL_TRIALS trial_result · 2024-08-21Clinical Trial Update: Efficacy and Safety Study of DURVALUMAB Maintenance in Patients With Stage III Non-Small Cell Lung Cancer
Clinical trial update describing a maintenance therapy study with durvalumab in stage III non-small cell lung cancer, focusing on efficacy a…
-
CLINICAL_TRIALS research · 2024-08-21Clinical Trial Update: LIquid BIopsies in Patients Presenting Non-small Cell Lung Cancer
This clinical trial update notes a study focused on evaluating liquid biopsies in patients presenting with non-small cell lung cancer. The t…
-
CLINICAL_TRIALS trial_result · 2024-08-20Clinical Trial Update: The Study of Tusamitamab Ravtansine (IBI126) Combined With Sintilimab and Tusamitamab Ravtansine (IBI126) Combined With Sintilimab Plus Platinum-based Chemotherapy and Pemetrexed in Subjects With CEACAM5 Positive Expression Advanced/Metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC) [Phase 2]
A Phase 2 study evaluating Tusamitamab Ravtansine (IBI126) with Sintilimab, with or without platinum-based chemotherapy and pemetrexed, in C…
-
CLINICAL_TRIALS trial_result · 2024-08-20Clinical Trial Update: QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors [Phase 1, Phase 2]
This update reports the termination of a Phase 1/2 trial of AMG 655 in combination with AMG 479 for advanced, refractory solid tumors, with …
-
CLINICAL_TRIALS other · 2024-08-20Clinical Trial Update: A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer [Phase 1, Phase 2]
This entry describes a Phase I/II clinical trial of UCB4594 for multiple advanced solid tumors, including head and neck squamous cell carcin…
-
FDA approval · 2024-08-19FDA Approved: LAZCLUZE — Original Application (Janssen Biotech, Inc.)
FDA approved Lazertinib (LAZCLUZE) from Janssen Biotech, Inc. as the original application NDA for adult patients with non-small cell lung ca…
-
FDA label_change · 2024-08-19FDA Approved: RYBREVANT — Supplemental Application (Janssen Biotech, Inc.)
FDA approved a supplemental application for Rybrevant (amivantamab-vmjw) submitted by Janssen Biotech, Inc.
-
CLINICAL_TRIALS trial_result · 2024-08-19Clinical Trial Update: SRT for Residual Oligometastases of NSCLC After 3rd Generation EGFR-TKIs [Phase 2]
Phase 2 clinical trial evaluating stereotactic radiotherapy (SRT) for residual oligometastases in non-small cell lung cancer after third-gen…
-
CLINICAL_TRIALS research · 2024-08-16Clinical Trial Update: A RC198 Study in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors [Phase 1]
RemeGen's RC198 is being evaluated in a Phase 1 study across locally advanced unresectable or metastatic solid tumors, including melanoma, u…
-
CLINICAL_TRIALS trial_result · 2024-08-16Clinical Trial Update: The Impact of Probiotic on Survival and Treatment Response in Metastatic Non-small Cell Lung Cancer Patients [NA]
This clinical trial update investigates whether probiotic supplementation affects survival and treatment response in metastatic non-small ce…
-
CLINICAL_TRIALS research · 2024-08-16Clinical Trial Update: A Safety and Efficacy Study of Bevacizumab, Paclitaxel, Carboplatin Compared to Avastin® in Non-Small Cell Lung Cancer [Phase 3]
Phase 3 safety and efficacy study evaluating a Bevacizumab-based combination with Paclitaxel and Carboplatin in non-small cell lung cancer; …
-
CLINICAL_TRIALS research · 2024-08-16Clinical Trial Update: CSF CTC-Capture-Guided EGFR-TKI and Bevacizumab Combination Therapy in EGFR-Mutant Advanced NSCLC [EARLY_Phase 1]
An early-phase (Phase 1) clinical trial update evaluating a CSF CTC-capture-guided combination of EGFR-TKI and bevacizumab in EGFR-mutant ad…
-
CLINICAL_TRIALS trial_result · 2024-08-15Clinical Trial Update: Local Recurrence Prediction of by Texture Analysis Derived From Positron Emission Tomography (PET / CT) Imaging of Non-small Cell Lung Cancer (NSCLC) Treated With Stereotactic Radiotherapy (SBRT) (Retros MUMOFRAT)
A retrospective analysis investigates whether texture features from FDG PET/CT can predict local control in non-small cell lung cancer treat…
-
CLINICAL_TRIALS trial_result · 2024-08-15Clinical Trial Update: A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002) [Phase 2]
Phase 2 study MK-2140-002 evaluating Zilovertamab vedotin (VLS-101) in solid tumors including triple-negative breast cancer and non-small-ce…
-
CLINICAL_TRIALS research · 2024-08-15Clinical Trial Update: Olanzapine Impact on First-line Immunotherapy for Advanced EGFR-negative NSCLC [Phase 2]
A Phase 2 trial is evaluating whether olanzapine may influence outcomes when combined with first-line immunotherapy in advanced EGFR-negativ…
-
CLINICAL_TRIALS trial_result · 2024-08-15Clinical Trial Update: Advanced Lung Tumor Treated by Osimertinib Plus Anlotinib [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating the combination of osimertinib and anlotinib for advanced non-small cell lung cancer with EGFR mutations…